Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.
Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.
More about Keymed Biosciences, Inc.
Keymed Biosciences, Inc. is a company focused on the biotechnology industry, developing innovative therapeutic products. The company’s primary products include humanized antibodies targeting specific proteins involved in inflammatory processes, with a market focus on diseases such as atopic dermatitis and chronic rhinosinusitis.
YTD Price Performance: 2.43%
Average Trading Volume: 1,583,455
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$8.28B
For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.